Sector News

Japan’s Otsuka to buy Avanir for $3.5 billion ahead of patent cliff

December 2, 2014
Life sciences
(Reuters) – Japanese drugmaker Otsuka Holdings Co Ltd plans to buy U.S.-based Avanir Pharmaceuticals Inc for about $3.5 billion to expand its neurologic drug portfolio ahead of an expiration of a key drug patent.
 
Otsuka said subsidiary Otsuka Pharmaceutical Co Ltd would pay $17 per share in cash, or a premium of 13.3 percent to Avanir’s closing price on Monday.
 
The deal, Otsuka’s biggest according to Thomson Reuters data, comes as the company aims to beef up its product pipeline ahead of a so-called “patent cliff” after April 2015, when its U.S. patent for schizophrenia drug Abilify expires and opens the way to generic competition.
 
Its global sales of Abilify totaled 575.7 billion yen ($5 billion) in the last fiscal year, around 40 percent of the total for Otsuka Holdings. The United States is the biggest market for the drug.
 
Japanese companies, helped by cash-rich balance sheets and encouraged by an ageing domestic population, are looking overseas for growth.
 
Otsuka will launch a tender offer within 10 business days to purchase all outstanding shares of Avanir, the companies said. The deal is expected to close in the first quarter of 2015.
 
Otsuka Pharmaceutical President Taro Iwamoto said the deal would “bring together Otsuka’s experience and business track record in the area of mental illnesses with Avanir’s strengths in neurologic diseases”, according to a statement.
 
Avanir developed Nuedexta, which treats pseudobulbar affect, a neurological disorder characterized by involuntary outbursts of crying or laughter.
 
But it failed to win approval from the U.S. Food and Drug Administration for a migraine drug device in November, a few weeks after the regulator had raised questions regarding some data submitted as part of the marketing application.
 
After the deal, Avanir will operate as a unit of Otsuka America Inc and will partner with Otsuka to enhance its development and marketing efforts in central nervous system-related disorders.
 
Goldman Sachs advised Otsuka, while Centerview Partners advised Avanir.
 
(1 US dollar = 118.8800 Japanese yen)
 
(Reporting by Ritsuko Ando in Tokyo and Neha Dimri in Bengaluru; Editing by Gopakumar Warrier and Jane Baird)

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend